Page last updated: 2024-10-20

pyrazinamide and Parkinson Disease

pyrazinamide has been researched along with Parkinson Disease in 1 studies

pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.

Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kawachi, M1
Kono, N1
Kiyokawa, H1
Mineo, I1
Nakajima, H1
Shimizu, T1
Yorifuji, S1
Kuwajima, M1
Tarui, S1

Other Studies

1 other study available for pyrazinamide and Parkinson Disease

ArticleYear
Decreased renal clearance of xanthine and hypoxanthine in a patient with renal hypouricemia: a new defect in renal handling of purines.
    Nephron, 1992, Volume: 61, Issue:4

    Topics: Humans; Hypoxanthine; Hypoxanthines; Kidney Diseases; Male; Metabolic Clearance Rate; Middle Aged; P

1992